Related Experiment Video

Updated: Jul 6, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.1K

Roles of Rictor alterations in gastrointestinal tumors (Review)

Ruizhen Cao1, Shuilong Guo1, Li Min1

  • 1Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing 100050, P.R. China.

Oncology Reports
|January 8, 2024
PubMed

Insights

Rictor, a key part of mTORC2 signaling, is frequently altered in gastrointestinal cancers and linked to poor outcomes. Understanding Rictor

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Gastrointestinal tumors are a leading cause of cancer mortality.
  • Mammalian target of rapamycin (mTOR) signaling is often dysregulated in cancers.
  • Rictor, a component of mTOR complex 2 (mTORC2), plays a role in the PI3K/Akt pathway and is frequently altered in gastrointestinal tumors, correlating with chemotherapy resistance and adverse outcomes.

Purpose of the Study:

  • To review Rictor's mutation and biological functions (cell proliferation, angiogenesis, apoptosis, autophagy, drug resistance) in tumors.
  • To discuss Rictor's specific roles in colorectal, hepatobiliary, gastric, esophageal, pancreatic cancers, and cholangiocarcinoma.
  • To examine current and future prospects for Rictor-targeted therapies, focusing on inhibiting Akt activation.

Main Methods:

  • Literature review and critical discussion of existing research on Rictor in gastrointestinal cancers.
  • Analysis of Rictor's involvement in key cancer hallmarks.
  • Evaluation of therapeutic strategies targeting Rictor/mTORC2 signaling.

Main Results:

  • Rictor alterations are common in gastrointestinal tumors and associated with poor prognosis.
  • Rictor influences critical cancer processes including proliferation, angiogenesis, apoptosis, autophagy, and drug resistance.
  • Targeting Rictor, particularly via Akt inhibition, presents a potential therapeutic avenue, though mechanistic details require further elucidation.

Conclusions:

  • Rictor is a significant factor in gastrointestinal cancer development and progression.
  • Further research into Rictor's precise mechanisms is crucial for developing effective targeted therapies.
  • Understanding Rictor is key to overcoming therapy resistance in gastrointestinal cancers.
Keywords:
AktPI3KRictorgastrointestinal tumorsmTOR

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.4K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.0K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K